<DOC>
	<DOCNO>NCT02207491</DOCNO>
	<brief_summary>To evaluate ocular hypotensive efficacy ocular systemic safety AR-13324 Ophthalmic Solution , 0.02 % compare active comparator Timolol maleate Ophthalmic Solution , 0.5 %</brief_summary>
	<brief_title>Double-masked Study AR-13324 Ophthalmic Solution Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subject Inclusion criterion : 1 . 02 year age 18 year great . 2 . Diagnosis open angle glaucoma ocular hypertension 3 . Unmedicated ( postwashout ) IOP &gt; 20 mm Hg &lt; 27 mm Hg study eye 2 qualification visit . 4 . Corrected visual acuity eye equivalent 20/200 . 5 . Able willing give sign inform consent ( parent guardian consent pediatric patient ) follow study instruction . Subject exclusion criterion Ophthalmic : 1 . Glaucoma : pseudoexfoliation pigment dispersion component , history angle closure , narrow angle . Note : Previous laser peripheral iridotomy NOT acceptable . 2 . Intraocular pressure ≥27 mm Hg ( unmedicated ) eye ( individual exclude criterion allow attempt requalification ) , use two ocular hypotensive medication within 30 day screen . Note : fix dose combination count two medication . 3 . Known hypersensitivity component formulation use ( benzalkonium chloride , etc . ) , topical anesthetic beta adrenoceptor antagonist . 4 . Previous glaucoma intraocular surgery glaucoma laser procedures either eye 5 . Refractive surgery either eye . 6 . Ocular trauma either eye within six month prior screen , ocular surgery nonrefractive laser treatment within three month prior screen . 7 . Recent current evidence ocular infection inflammation either eye . Current evidence clinically significant blepharitis , conjunctivitis , history herpes simplex zoster keratitis screen either eye . 8 . Ocular medication either eye kind within 30 day screen . 9 . Clinically significant ocular disease either eye ( e.g. , corneal edema , uveitis , severe keratoconjunctivitis sicca ) might interfere study , include glaucomatous damage severe washout ocular hypotensive medication one month judge safe . 10 . Central corneal thickness either eye great 600 µm screening . 11 . Any abnormality either eye prevent reliable applanation tonometry either eye . Systemic : 12 . Clinically relevant abnormality ( determined investigator ) laboratory test screen may impact study . 13 . Known hypersensitivity contraindication betaadrenoceptor antagonist ( e.g. , chronic obstructive pulmonary disease bronchial asthma ; abnormally low blood pressure heart rate ; second third degree heart block congestive heart failure ; severe diabetes ) . 14 . Clinically significant systemic disease ( e.g. , uncontrolled diabetes , myasthenia gravis , hepatic , renal , endocrine cardiovascular disorder ) might interfere study . 15 . Participation investigational study within 30 day prior screen . 16 . Changes systemic medication could effect intraocular pressure within 30 day prior screen , anticipate study . 17 . Women childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine pregnancy test result screen examination must intend become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Glaucoma</keyword>
</DOC>